FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 644 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer November 5, 2019 Immunotherapy Plus Chemotherapy Helps People With Advanced Nasopharyngeal Cancer: The ASCO... April 18, 2022 How could proposed changes to data protection laws affect research? December 8, 2021 FDA Approves Abatacept for Prophylaxis of Acute Graft Versus Host Disease February 1, 2022 Load more HOT NEWS President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All... ESMO Welcomes European Parliament (EP) Draft Report on Psychosocial Risks at... ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast...
